Immunotherapy with checkpoint inhibitors is well established as an effective treatment for
non-small cell lung cancer and melanoma. The list of approved indications for treatment with …

The recent development of immune checkpoint inhibitors (ICIs) has led to promising
advances in the treatment of patients with NSCLC and SCLC with advanced or metastatic …

Abstract Objectives The Blueprint (BP) Programmed Death Ligand 1 (PD-L1)
Immunohistochemistry Comparability Project is a pivotal academic/professional society and …

Lung cancer is the leading cause of cancer-related deaths worldwide. It exhibits, at the
mesoscopic scale, phenotypic characteristics that are generally indiscernible to the human …

Background In the phase III IMpassion130 study, atezolizumab plus nab-paclitaxel (A+ nP)
showed clinical benefit in advanced or metastatic triple-negative breast cancer patients who …

Different clones, protocol conditions, instruments, and scoring/readout methods may pose
challenges in introducing different PD-L1 assays for immunotherapy. The diagnostic …

Lung cancer remains a leading cause of cancer‐related mortality worldwide with the poor
prognosis. Encouragingly, immune checkpoint blockade targeting programmed death‐1 (PD …

In recent years, immunotherapy has revolutionized and changed the standard of care in
patients with advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors …

Recent clinical trials have shown the promising therapeutic effects of pembrolizumab and
nivolumab in patients with advanced gastric cancer. Currently, the programmed death ligand …

Programmed cell death ligand-1 (PD-L1) expression levels in patient tumor samples have
proven clinical utility across various cancer types. Several independently developed PD-L1 …